ALK

(A-L-K), spoken as individual letters; sometimes pronounced "alk" in clinical shorthand

ALK is a gene that produces a protein involved in cell growth signaling. When the ALK gene becomes abnormally rearranged, it can drive uncontrolled cell growth and lead to cancer. ALK rearrangements are found in a small subset of non-small cell lung cancers (NSCLC), where they serve as a target for a class of drugs called ALK inhibitors.

Origin

ALK was first identified in anaplastic large-cell lymphoma in the 1990s, where a chromosomal rearrangement was found to activate it abnormally, hence the name. The word "kinase" comes from the Greek kinesis (movement), reflecting the enzyme's role in transferring chemical signals within cells. ALK rearrangements in lung cancer were identified in 2007 and have since become one of the most important biomarkers in lung cancer treatment.

Significance in Asbestos Context

Asbestos exposure is a well-established cause of non-small cell lung cancer, and roughly 3–5% of NSCLC cases, including some asbestos-related cases, carry ALK rearrangements. If your tumor tests ALK-positive, you may be a candidate for targeted ALK inhibitor therapy (such as alectinib, brigatinib, or lorlatinib), which is often more effective and better tolerated than standard chemotherapy. ALK status can also become a flashpoint in litigation: defense experts may argue that an ALK-driven cancer is "genetic" rather than asbestos-caused. This argument confuses how a cancer grows at the molecular level with what caused it. Asbestos fibers cause DNA damage and chromosomal breakage, and asbestos-exposed workers can develop lung cancers carrying any molecular profile, including ALK rearrangements. Your legal team will likely need an oncology expert to explain that molecular alterations and environmental causation are not mutually exclusive.

Example Sentence

After Maria's lung cancer was found to harbor an ALK rearrangement, her oncologist started her on an ALK inhibitor, and her attorney prepared expert testimony to rebut any defense argument that the molecular finding ruled out her decades of workplace asbestos exposure as a cause.

Related Terms

Non-small cell lung cancer (NSCLC), ALK inhibitor, biomarker, molecular testing, oncogene, next-generation sequencing (NGS), EGFR, ROS1

Notes

• If you or a loved one has been diagnosed with NSCLC, ask the oncologist whether comprehensive molecular testing has been performed, including ALK, EGFR, ROS1, KRAS, BRAF, and PD-L1. A positive ALK result can open the door to targeted therapy that significantly improves survival.
• Ask which testing method was used: fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), or next-generation sequencing (NGS). NGS is preferred because it tests for multiple actionable mutations from a single tissue sample.
• Preserve all molecular pathology reports along with the original biopsy report. These documents matter for treatment decisions and for your legal claim. If testing was not done, ask whether stored (archived) tumor tissue can still be tested.
• ALK rearrangements are more common in younger patients and in never-smokers or light smokers. If you have asbestos-related lung cancer with little or no smoking history, ALK testing is especially important.
• If an ALK inhibitor stops working due to resistance, second- and third-generation ALK inhibitors are available. Ask your oncologist about the sequence of treatments and whether repeat biopsy or liquid biopsy is appropriate at progression.
• ALK rearrangements are rarely found in mesothelioma. This term is most relevant to patients with asbestos-related lung cancer.